# Taysha Gene Therapies, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Taysha Gene Therapies, Inc.). ## Overview Taysha Gene Therapies, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is being developed for Rett syndrome, and the company’s pipeline is centered on CNS gene therapy candidates. ## Products & services • TSHA-102 gene therapy for Rett syndrome • AAV-based CNS gene therapy programs • Preclinical and clinical development of monogenic disease therapies • Manufacturing process development for gene therapy candidates - **Lead clinical program** (100%) — TSHA-102 and related clinical development activities for Rett syndrome. - **Pipeline gene therapy programs** (0%) — Additional AAV-based CNS gene therapy candidates in preclinical or early development. - **Process development and manufacturing** (0%) — CMC, scale-up, and cGMP manufacturing support for clinical and future commercial supply. - TSHA-102 gene therapy for Rett syndrome - AAV-based CNS gene therapy programs - Preclinical and clinical development of monogenic disease therapies - Manufacturing process development for gene therapy candidates ## Customers Taysha does not sell approved products today; its direct counterparties are primarily regulators, clinical trial sites, contract manufacturers, and research collaborators that enable development. If approved, its eventual customers would be patients with severe CNS genetic diseases, with treatment access likely mediated by specialty healthcare providers and payers. - **Clinical trial patients** (primary) — Females with Rett syndrome enrolled in REVEAL Phase 1/2 studies to evaluate TSHA-102. - **Clinical investigators and trial sites** (primary) — Hospitals and research centers that administer study drug and collect safety/efficacy data. - **Contract manufacturers** (secondary) — CMOs that produce cGMP gene therapy material for clinical trials and future supply. - **Research collaborators and licensors** (secondary) — Academic and institutional partners that provide technology, know-how, or licensed IP. - **Future healthcare providers and payers** (emerging) — Specialty neurology providers and reimbursement decision-makers for any approved therapy. - Clinical trial patients enrolled in Rett syndrome studies - Investigators and trial sites running REVEAL studies - Contract manufacturing organizations producing cGMP material - Research collaborators and licensors supporting pipeline development - Future specialty neurology providers and payers, if approved ## Geography The company is headquartered in the United States and conducts its development, regulatory, and financing activities from there. Its lead program is being advanced through U.S.-based FDA interactions and clinical trials, while future commercialization would depend on approvals in the U.S. and potentially other jurisdictions. - Headquartered in the United States - Clinical and regulatory work is centered on FDA pathways - Future commercialization would likely begin in the U.S. - Potential expansion could include foreign regulatory markets ## Strategy Taysha’s strategy is to advance TSHA-102 through clinical development and regulatory review while building the manufacturing and quality capabilities needed for potential commercialization. It also seeks to broaden its CNS gene therapy pipeline through development, in-licensing, or acquisition of additional product candidates and technologies. - **Advance TSHA-102 in Rett syndrome** (short-term) — The company is highly dependent on its lead clinical program for value creation. - **Strengthen regulatory and clinical capabilities** (short-term) — Later-stage development and BLA preparation require capabilities the company has not yet fully executed at scale. - **Build manufacturing and commercialization readiness** (medium-term) — Gene therapy programs require specialized CMC, supply chain, and launch infrastructure before approval. - **Expand the pipeline beyond TSHA-102** (medium-term) — A broader portfolio can reduce single-asset dependence and create additional development optionality. - Advance TSHA-102 through REVEAL clinical trials - Pursue FDA and future foreign regulatory approvals - Scale manufacturing and CMC capabilities for gene therapy supply - Expand the CNS gene therapy pipeline through licensing or acquisition - Build commercialization infrastructure for a potential launch ## Risks Taysha is exposed to the high failure rate of clinical-stage biotechnology, where early signals may not translate into pivotal trial success or regulatory approval. The company is also concentrated in a single lead asset, so setbacks in TSHA-102, manufacturing, or regulatory review could materially affect its prospects. - **Clinical development failure** [critical] — TSHA-102 must show durable safety and efficacy in later-stage studies to support approval. - **Regulatory delay or rejection** [high] — The company has limited experience with pivotal trials and BLA submissions, increasing execution risk. - **Single-asset concentration** [critical] — The company is substantially dependent on one clinical candidate for value creation. - **Manufacturing and CMC execution** [high] — AAV gene therapies require specialized process development, scale-up, and quality control. - **Financing and dilution risk** [high] — As a pre-revenue biotech, continued development depends on external capital and access to markets. - Clinical data may change as more patients are treated and followed - Late-stage trials may fail even after encouraging early results - Regulatory review can be delayed, limited, or rejected - Heavy dependence on TSHA-102 creates single-asset concentration risk - Gene therapy manufacturing and scale-up are complex and costly ## Accounting As a clinical-stage biotech, Taysha’s reported results are driven mainly by research and development spending, stock-based compensation, and non-cash items rather than product revenue. Investors should watch estimates tied to clinical and manufacturing assets, stock compensation, and any impairment or deferred revenue adjustments that can affect period-to-period comparability. - **Research and development expense recognition** — Affects operating loss and cash burn - **Stock-based compensation** — Affects reported operating expenses and net loss - **Asset impairment** — Can create non-cash charges in operating results - **Deferred revenue** — Can affect revenue timing and operating cash flow - No product revenue yet, so expenses dominate reported results - R&D spending is the main operating cost and can be lumpy by trial stage - Stock-based compensation is a meaningful non-cash expense - Impairment charges can arise on manufacturing or lab assets - Deferred revenue changes can affect operating cash flow --- *Last updated: 2026-04-29T05:03:06.434236+00:00*